Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

NCT03870945

Conditions
B-cell Non Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Klinikum Augsburg, II. Med. Klinik Haematologie / Onkologie Augsburg, Bavaria, Germany
  • University Hospital Cologne - Department for Internal Medicine I Cologne, North Rhine-Westphalia, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Department of Stem Cell Transplantation Hamburg, Germany
View Trial Details
Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

NCT03190330

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Avron Hospitals Pvt. Ltd Ahmedabad, India
  • Post Graduate Institute of Medical Education And Research PGIMER Chandigarh, India
  • Basavatarakam Indo-American Hospital Hyderabad, India
  • Bhagwan Mahaveer Cancer Hospital & Research Centre Jaipur, India
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT03384654

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • UCSF Benioff Children's Hospital Oakland Oakland, California, United States
  • Children's Hospital Orange County Orange, California, United States
View all 53 locations
View Trial Details
Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

NCT01974440

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Gilbert, Arizona, United States
  • Campbell, California, United States
  • Duarte, California, United States
  • La Jolla, California, United States
View all 135 locations
View Trial Details
Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

NCT04042376

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • The First Hospital of Jilin University Changchun, China
  • First affiliated Hospital of Zhejiang University Hangzhou, China
  • Institute of Hematology and Blood Diseases Hospital Tianjin, China
  • Wuhan Union Hospital Wuhan, China
View Trial Details
Completed

Short Course Daratumumab in Patients With Multiple Myeloma

NCT03490344

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memoral Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memoral Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

NCT04062448

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Kameda Medical Center Chiba, Japan
  • National Cancer Center Hospital Chūōku, Japan
  • National Hospital Organization Kumamoto Medical Center Kumamoto, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Japan
View Trial Details
Completed

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

NCT03941860

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
  • Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California, United States
  • Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California, United States
View all 222 locations
View Trial Details
Completed

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04436107

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
View Trial Details

Related conditions